Search Within

Gynecology Disease Management Team

Formats
  1. Journal Article (2473)
  2. Meeting Abstract (2112)
  3. Book Section (226)
  4. Review (135)
  5. Editorial (88)
  6. Guidelines (39)
  7. Correspondence (19)
  8. Conference Paper (16)
  9. Miscellaneous (13)
  10. Research Letter (12)
  11. Book Whole (11)
Groups
  1. Surgery (2362)
  2. Department of Medicine (2268)
  3. Solid Tumor Oncology Division (2217)
  4. GDMT, Surgery (1974)
  5. GDMT, Medicine (1910)
  6. Gynecologic Medicine Service (1877)

More Groups

People
  1. Nadeem Abu-Rustum (902)
  2. Robert Soslow (797)
  3. Dennis Chi (716)
  4. Britta Weigelt (646)
  5. Carol Aghajanian (615)
  6. Mario Leitao (582)

More People

Years
  1. 2025 (161)
  2. 2024 (308)
  3. 2023 (332)
  4. 2022 (361)
  5. 2021 (308)
  6. 2020 (356)

More Years

Publications
  1. Gynecologic Oncology (950)
  2. Journal of Clinical Oncology (543)
  3. Modern Pathology (354)
  4. International Journal of Gynecological Cancer (321)
  5. Laboratory Investigation (311)
  6. International Journal of Radiation Oncology, Biology, Physics (223)

More Publications

Publishers
  1. Elsevier B.V. (1001)
  2. American Society of Clinical Oncology (598)
  3. Lippincott Williams & Wilkins (584)
  4. Elsevier Inc. (481)
  5. Nature Publishing Group (424)
  6. Nature Research (356)

More Publishers

Results (5144)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial
    Meeting Abstract

    Economides, M. P.; Milowsky, M. I.; O'Donnell, P. H.; Alva, A. S.; Kollmeier, M.; Rose, T. L.; Pitroda, S. P.; Rosenberg, J. E.; Hochman, T.; Goldberg, J. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study
    Meeting Abstract

    Moore, K. N.; Sabanathan, D.; Du, Y.; Duan, H.; Li, X.; Wang, F.; Marathe, O.; Yang, H.; Makker, V.; Growdon, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Liu, D.; Makker, V.; Buonocore, D. J.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Johnson, A.; Offin, M.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer
    Meeting Abstract

    Yap, T. A.; Elhaddad, A. M.; Grisham, R. N.; Hamm, J. T.; Marks, D. K.; Shapiro, G.; Le Corre, C.; Li, J.; Lin, T. T.; Liu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis
    Meeting Abstract

    Elkrief, A.; Nicholas, W.; Smith, N.; Dai, A.; Slingerland, J. B.; Aleynick, N.; Lumish, M. A.; Giardina, P.; Chaft, J. E.; Chapman, P. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial
    Meeting Abstract

    Harter, P.; Trillsch, F.; Okamoto, A.; Reuss, A.; Kim, J. W.; Rubio-PeĢrez, M. J.; Vardar, M. A.; Scambia, G.; Tredan, O.; Nyvang, G. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results
    Meeting Abstract

    Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S. N.; Martin, A. G.; Jung, K. H.; Lugowska, I. A.; Manso, L.; Manzano, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The significance of International Federation of Gynecology and Obstetrics grading in microsatellite instability-high and POLE-mutant endometrioid endometrial carcinoma
    Journal Article

    Kertowidjojo, E.; Momeni-Boroujeni, A.; Rios-Doria, E.; Abu-Rustum, N.; Soslow, R. A.
    Modern Pathology (2023)

    Fulltext@MSK | Save
  • Interobserver reproducibility in assessing eosinophilic cells in ovarian serous borderline tumors to predict BRAF mutational status
    Journal Article

    Chui, M. H.; Murali, R.; Soslow, R. A.; Matrai, C.; Xing, D. Y.; Vang, R.
    International Journal of Gynecological Pathology (2023)

    Fulltext@MSK | Save
  • Correspondence on 'ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer - Update 2023'
    Research Letter

    Pareja, R.; Heredia, F.; Leitao, M.
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save